Retinoblastoma protein expression in endometrial hyperplasia and carcinoma

被引:25
作者
Niemann, TH
Yilmaz, AG
McGaughy, VR
Vaccarello, L
机构
[1] OHIO STATE UNIV HOSP, DIV GYNECOL ONCOL, COLUMBUS, OH 43235 USA
[2] ARTHUR G JAMES CANC HOSP & RES INST, COLUMBUS, OH 43235 USA
关键词
D O I
10.1006/gyno.1997.4664
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The retinoblastoma (RB) gene was the first defined tumor suppressor gene. While originally described in retinoblastoma, more recently alterations in RE have been described in a number of other human neoplasms and there has been a suggestion that alteration of RE may play a significant role in the development of endometrial carcinoma. We examined RE protein expression by immunohistochemistry in a series of cases including normal endometrium, endometrial hyperplasia, and endometrial carcinoma. A relatively homogeneous pattern of staining was observed in proliferative endometrium, while weak or absent reactivity was noted in secretory endometrium. A heterogeneous pattern of reactivity was observed in 10/10 cases of hyperplasia, 66/70 cases of endometrial adenocarcinoma, and 7/7 cases of uterine carcinosarcoma. An altered pattern of reactivity was observed in the remaining 4/70 cases of adenocarcinoma. All of the cases with altered reactivity were high grade neoplasms. We conclude that alteration of RB protein expression is uncommon in endometrial adenocarcinoma and when it does occur, it may represent a late event in carcinogenesis. (C) 1997 Academic Press.
引用
收藏
页码:232 / 236
页数:5
相关论文
共 28 条
  • [21] Scully RE., 1994, Histological typing of female genital tract tumours
  • [22] SHIMIZU E, 1994, ONCOGENE, V9, P2441
  • [23] ABNORMAL EXPRESSION OF THE RETINOBLASTOMA GENE IN OVARIAN NEOPLASMS AND CORRELATION TO P53 AND K-RAS MUTATIONS
    TAYLOR, RR
    LINNOILA, RI
    GERARDTS, J
    TENERIELLO, MG
    NASH, JD
    PARK, RC
    BIRRER, MJ
    [J]. GYNECOLOGIC ONCOLOGY, 1995, 58 (03) : 307 - 311
  • [24] XU HJ, 1991, CANCER RES, V51, P2735
  • [25] XU HJ, 1991, ONCOGENE, V6, P1139
  • [26] XU HJ, 1995, ADV ANAT PATHOL, V2, P213
  • [27] YOKOTA J, 1988, ONCOGENE, V3, P471
  • [28] ZHANG X, 1994, CANCER RES, V54, P4177